Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Aduhelm

FDA grants full approval to new Alzheimer’s drug - Roll Call

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Roll Call

For Alzheimer’s patients, a controversial drug brings hope

TAMPA, Fla. -- At 53, Michele Hall was at the height of her legal career. She’d just sent her three kids to college. She had decades ahead with her husband Doug — after nearly 30 years of marriage, the couple looked forward to celebrating 30 more.

Tribune News Service

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Commentary: Medicare is cleaning up the FDA’s mess on Biogen’s Alzheimer’s drug

Medicare has decided once and for all not to pay for Biogen’s new Alzheimer’s drug Aduhelm unless patients are enrolled in a clinical study.

Tribune News Service

Biogen lays out awaited Alzheimer’s drug data in obscure journal

Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after U.S. regulators cleared the treatment.

Tribune News Service

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Alzheimer’s patients divided on costly new drug: a ‘magic pill’ or ‘risk I’m willing to take’

Medicare has proposed limiting coverage of Aduhelm. Key groups representing patients and families are pressing to make it more widely available. Among people facing the disease, the outlook is more nuanced.

Chicago Sun-Times

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.

Roll Call

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Benzinga

People

Doug

144 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Securities and Exchange Commission

185 stories

Federal Trade Commission

Alzheimer Association

19 stories

Leqembi

18 stories

University of Sourn California

16 stories

Aduhelm

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.